A key drug is at the center of a debate over abortion access. Tightening prescribing rules for this medication is being considered by a panel of federal judges. This case is part of a larger effort to restrict abortion access, which has been ongoing since a major court decision allowed states to make their own rules.

The US Food and Drug Administration is also reviewing its rules and may call for changes. This review could potentially take precedence over any court decisions.

Further details about the case and its potential implications are available from the source.